Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm ...
In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback